NEW YORK, April 27, 2026, 17:05 (EDT)
- Oruka reported that 63.5% of psoriasis patients treated with ORKA-001 achieved complete skin clearance at 16 weeks.
- The stock was recently at $76.39, up roughly 10.5%, having earlier hit an intraday peak of $114.49.
- Later on Monday, the company kicked off plans for a $500 million public offering, also giving underwriters the chance to pick up another $75 million.
Oruka Therapeutics jumped to secure $500 million through stock and pre-funded warrants Monday, following a spike in its shares after interim results from its investigational psoriasis treatment. The surge also sparked new comparisons to big-name drugs from AbbVie and UCB.
The timing works in Oruka’s favor. Investors, on the hunt for fresh players in the psoriasis landscape, took notice as the latest data landed. In this space, dosing ease and strong skin-clearance numbers influence prescribing choices. ORKA-001, Oruka’s candidate, is designed as a longer-acting injectable—potentially needed just once or twice a year, according to the company.
Out of 63 patients given ORKA-001, 40 reached PASI 100 at Week 16, Oruka said—that’s 63.5%, showing full clearance based on the Psoriasis Area and Severity Index. Just one patient on placebo, from a group of 21, saw results that strong.
The trial hit its secondary endpoints, too. According to Oruka, 82.5% of patients on treatment achieved PASI 90—meaning at least a 90% improvement in their skin. On top of that, 84.1% scored a 0 or 1 on the Investigator Global Assessment, which indicates their skin was rated clear or nearly clear.
Safety profile, in this limited study, came through looking solid. Among ORKA-001 recipients, 50.8% experienced treatment-emergent adverse events, compared to 57.1% for placebo. Notably, the treatment group saw no serious adverse events and nobody dropped out over side effects.
ORKA-001, a monoclonal antibody developed in the lab to target IL-23p19—an immune signal associated with inflammation in psoriasis—has delivered some fresh Phase 1 results. According to the company, after just one 600 mg dose, drug concentrations remained above the desired trough for a full 52 weeks, backing up the idea that a single annual dose could be enough.
Joana Goncalves, the company’s Chief Medical Officer, called the data the “top end” of what Oruka had hoped for on efficacy, tolerability, and the potential for a durable response. Dr. Bruce Strober, Yale dermatology professor and lead investigator, pointed out that getting down to one or two doses a year would mark “a major step forward.” Oruka Therapeutics, Inc.
Barclays analysts pointed to a best-in-class profile in the data, noting numerical superiority over AbbVie’s Skyrizi and results on par with UCB’s Bimzelx, according to Reuters. It’s worth noting, though, Oruka’s drug wasn’t put up directly against those treatments—an important caveat.
Jefferies analysts didn’t mince words, describing the results as an “outright win over Skyrizi,” Fierce Biotech reported. They’re sizing up the profile for potential sales in the $5 billion to $10 billion range, assuming it holds. Oruka CEO Lawrence Klein, meanwhile, told analysts the data might show a “category-winning profile.” Fierce Biotech
Oruka shares kicked off at $90.02, then surged as high as $114.49 before sliding back to $76.39—still up roughly 10.5% from the previous close. Trading was heavy, with volume topping 6.8 million shares. The stock’s path was anything but steady.
The financing announcement landed after the rally. Oruka noted the deal’s timing, size, and terms remain up in the air—it all depends on market and other conditions. Bookrunners listed: Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim Securities.
Clinical risk dominates here. EVERLAST-A brought in just 84 patients, and it’s still an interim Phase 2a — a far cry from the larger, pivotal studies regulators typically want for sign-off. Oruka pointed to longer-term results on the horizon: Week 28 efficacy and a 52-week follow-up for some patients should arrive in the back half of 2026. The next step, Phase 2b (EVERLAST-B), is supposed to deliver data in 2027.
If the stock sale gets priced under where the shares are trading, that could weigh on the price, and investors might get jittery about dilution. Oruka flagged both market and closing conditions as variables that could shift the outcome, according to the offering statement. The company’s trial disclosures also point to uncertainty around upcoming data and regulatory input.
